Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug–drug interaction model rats

By Kanazu Takushi   Okamura Noboru   Yamaguchi Yoshitaka   Baba Takahiko   Koike Masahiro  

Xenobiotica, Vol. 35, Iss. 4, 2005-04 ,pp. : 305-317

Informa Healthcare

Access to resources Recommend Favorite

Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans

By Kanazu T.   Yamaguchi Y.   Okamura N.   Baba T.   Koike M.  

Xenobiotica, Vol. 34, Iss. 5, 2004-05 ,pp. : 391-402

Informa Healthcare

Access to resources Recommend Favorite

Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats

By Kanazu T.   Yamaguchi Y.   Okamura N.   Baba T.   Koike M.  

Xenobiotica, Vol. 34, Iss. 5, 2004-05 ,pp. : 403-413

Informa Healthcare

Access to resources Recommend Favorite

Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

By Tachibana T.   Kato M.   Watanabe T.   Mitsui T.   Sugiyama Y.  

Xenobiotica, Vol. 39, Iss. 6, 2009-06 ,pp. : 430-443

Informa Healthcare

Access to resources Recommend Favorite

A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data

By Rioux Nathalie   Batonga Joëlle   Colombo Federico   Massé Jonathan   Zouki Christine   Ribadeneira Maria D.   Duan Jianmin   Bethell Richard C.  

Xenobiotica, Vol. 43, Iss. 7, 2013-07 ,pp. : 592-597

Informa Healthcare

Access to resources Recommend Favorite